SEC Form 4 · accession 0001209191-19-008648
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eiry Roberts
Officer — Chief Medical Officer
Period of report
Feb 7, 2019
Accepted (ET)
Feb 8, 2019 · 5:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $81.05 | Feb 7, 2019 | A | 66,673 | A | — | Feb 7, 2029 | Common Stock | 66,673 | 66,673 | D |
| Restricted StockF2,F3 | — | Feb 7, 2019 | A | 12,339 | A | — | — | Common Stock | 12,339 | 12,339 | D |
Explanation of responses
- F1Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.
- F2Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
- F3The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023.